Sitemap > Breaking Research > Cancer Immunotherapy
Displaying 751 - 800 of 1868 results
- Rapid generation of CMV pp65-specific T cells for immunotherapy.
- In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.
- Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).
- Panitumumab a novel drug in cancer treatment.
- Cloning and characterization of an adenoviral vector for highly efficient and doxycycline - suppressible expression of bioactive human single - chain interleukin 12 in colon cancer.
- Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12.
- Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
- Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
- An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
- Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors.
- Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase Peptide.
- A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.
- Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
- Synthesis of Glycocluster-Tumor Antigenic Peptide Conjugates for Dendritic Cell Targeting.
- The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
- Hyaluronic Acid-Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts.
- Human Mesenchymal Stem Cells Lack Tumor Tropism but Enhance the Antitumor Activity of Oncolytic Adenoviruses in Orthotopic Lung and Breast Tumors.
- Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study.
- Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy.
- A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism.
- A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
- Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.
- The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.
- IL-6-Encoding Tumor Antigen Generates Potent Cancer Immunotherapy Through Antigen Processing and Anti-apoptotic Pathways.
- Enhanced In Vivo Antitumor Efficacy of Poorly Soluble PDT Agent, Meso-Tetraphenylporphine, in PEG-PE-Based Tumor-Targeted Immunomicelles.
- Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
- Effect of a novel fully human monovalent antigen-binding fragment on the survival of cancer cell lines.
- Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.
- Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study.
- Targeted pharmaceutical nanocarriers for cancer therapy and imaging.
- Infliximab for GVHD therapy in children.
- Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer.
- TNF-{alpha}-based accentuation in cryoinjury--dose, delivery, and response.
- Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
- CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma.
- Adenovirus-mediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis.
- Therapeutic dendritic cell vaccination with Ag coupled to cholera toxin in combination with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV 16 expressing tumours.
- Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat Lymphoma.
- 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer.
- A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
- Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake.
- Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors.
- Doxorubicin Directs the Accumulation of Interleukin-12 Induced IFN{gamma} into Tumors for Enhancing STAT1 Dependent Antitumor Effect.
- TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
- Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats.
- Fluorescently Labeled Cetuximab to Evaluate Head and Neck Cancer Response to Treatment.
- Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
- In vivo imaging of T cell delivery to tumors after adoptive transfer therapy.
- Identification and Characterization of ErbB-3-Binding Protein-1 as a Target for Immunotherapy.
- A Novel Dual-targeted Lentiviral Vector Leads to Specific Transduction of Prostate Cancer Bone Metastases In Vivo After Systemic Administration.